Literature DB >> 29924296

ESMO Consensus Conference on malignant lymphoma: management of 'ultra-high-risk' patients.

M Hutchings1, M Ladetto2, C Buske3, P de Nully Brown4, A J M Ferreri5, M Pfreundschuh6, N Schmitz7, A Sureda Balari8, G van Imhoff9, J Walewski10.   

Abstract

The European Society for Medical Oncology (ESMO) consensus conference on malignant lymphoma was held on 20 June 2015 in Lugano, Switzerland, and included a multidisciplinary panel of 25 leading experts. The aim of the conference was to develop recommendations on critical subjects difficult to consider in detail in the ESMO Clinical Practice Guidelines. The following areas were identified: (1) the elderly patient, (2) prognostic factors suitable for clinical use and (3) the 'ultra-high-risk' group. Before the conference, the expert panel was divided into three working groups; each group focused on one of these areas in order to address clinically relevant questions relating to that topic. All relevant scientific literature, as identified by the experts, was reviewed in advance. During the consensus conference, each working group developed recommendations to address each of the questions devised by their group. These recommendations were then presented to the entire multidisciplinary panel and a consensus was reached. This manuscript presents recommendations regarding the management of the following 'ultra-high-risk' situations: (1) early central nervous system relapse of diffuse large B-cell lymphoma, (2) primary refractory Hodgkin lymphoma and (3) plasmablastic lymphoma. Results, including a summary of evidence supporting each recommendation, are detailed in this manuscript. All expert panel members approved this final article.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29924296     DOI: 10.1093/annonc/mdy167

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  6 in total

1.  Predictive impact of soluble interleukin-2 receptor and number of extranodal sites for identification of patients at very high risk of CNS relapse in diffuse large B-cell lymphoma.

Authors:  Takafumi Shichijo; Hiro Tatetsu; Kisato Nosaka; Yusuke Higuchi; Yoshitaka Kikukawa; Yoshitaka Inoue; Kosuke Toyoda; Jun-Ichirou Yasunaga; Masao Matsuoka
Journal:  EJHaem       Date:  2022-02-08

Review 2.  Advances in risk assessment and prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma.

Authors:  David Qualls; Jeremy S Abramson
Journal:  Haematologica       Date:  2018-12-20       Impact factor: 9.941

3.  Hemophagocytic Syndrome-Associated Variant of Methotrexate-Associated Intravascular Large B-Cell Lymphoma in a Rheumatoid Arthritis Patient.

Authors:  Yukiko Komeno; Minako Akiyama; Yasumi Okochi; Hitoshi Tokuda; Keiko Abe; Kuniko Iihara; Tomiko Ryu
Journal:  Case Rep Hematol       Date:  2019-09-11

4.  Obesity is associated with an impaired survival in lymphoma patients undergoing autologous stem cell transplantation.

Authors:  Sebastian Scheich; Julius C Enßle; Victoria T Mücke; Fabian Acker; Lukas Aspacher; Sebastian Wolf; Anne C Wilke; Sarah Weber; Uta Brunnberg; Hubert Serve; Björn Steffen
Journal:  PLoS One       Date:  2019-11-08       Impact factor: 3.240

5.  Case Report: Bortezomib Plus CDOP Followed by Sequential Autologous Hematopoietic Stem Cell Transplantation and Lenalidomide-Based Maintenance Therapy in Plasmablastic Lymphoma.

Authors:  Jiao Cai; Ling Qiu; Lei Ma; Nan Zhang; Fang-Yi Fan
Journal:  Front Med (Lausanne)       Date:  2021-12-03

6.  High-dose methotrexate is effective for prevention of isolated CNS relapse in diffuse large B cell lymphoma.

Authors:  Shin Yeu Ong; Sanjay de Mel; Nicholas Francis Grigoropoulos; Yunxin Chen; Yan Chin Tan; Melinda Si Yun Tan; Lawrence Cheng Kiat Ng; Yuh Shan Lee; Colin Phipps; Yeow Tee Goh; Kar Ying Yong; Xin Liu; Wee Joo Chng; Soon Thye Lim; Chandramouli Nagarajan
Journal:  Blood Cancer J       Date:  2021-08-12       Impact factor: 11.037

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.